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Abstract Subcellular fractionation revealed that a significant
fraction of total sphingosine kinase, the enzyme that phosphor-
ylates sphingosine to form the bioactive lipid metabolite
sphingosine-1-phosphate, resides in the nuclei of Swiss 3T3 cells,
localized to both the nuclear envelope and the nucleoplasm.
Platelet-derived growth factor, in addition to rapidly stimulating
cytosolic sphingosine kinase, also induced a large increase in
nucleoplasm-associated activity after 12^24 h that correlated
with progression of cells to the S-phase of the cell cycle and
translocation of sphingosine kinase^green fluorescent protein
fusion protein to the nuclear envelope. Our results add
sphingosine kinase to the growing list of lipid-metabolizing
enzymes associated with the nucleus, and suggest that sphingo-
sine-1-phosphate may also play a role in signal transduction in
the nucleus. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
The canonical model of lipid second-messenger action in-
volves the generation of bioactive lipid metabolites at the
plasma membrane that activate signaling cascades, leading
to the stimulation of activities in target organelles, including
the nucleus. However, it has become apparent that the nuclear
envelope is also an active participant in signaling cascades
involving induction of speci¢c types of nuclear lipid metabo-
lism [1].
Although still somewhat controversial, a substantial body
of literature has implicated ceramide and sphingosine in cell
growth arrest and apoptosis induced by cytokines, ionizing
radiation, anti-cancer drugs, growth factor withdrawal, and
various other apoptotic agents (reviewed in [2]), while a fur-
ther metabolite, sphingosine-1-phosphate (SPP), generally
promotes cell growth and survival [3]. Numerous studies
have demonstrated that activation of either neutral or acidic
sphingomyelinase plays an important role in apoptosis [4,5].
The observation that the composition and turnover of sphin-
gomyelin in the internal nuclear matrix changes during hep-
atocyte maturation [6] together with the detection of neutral
sphingomyelinase activity in both the nuclear membrane and
the chromatin fractions [7], led to the suggestion of a potential
role for nuclear sphingomyelin metabolites [8,9]. In agreement
with an apoptotic function of ceramide, activation of nuclear
sphingomyelinase leading to accumulation of ceramide and
sphingosine occurs after portal vein branch ligation, a proce-
dure which induces apoptosis of hepatocytes [10]. Moreover,
neutral sphingomyelinase activation, ceramide generation, and
apoptotic features (PARP cleavage, nuclear fragmentation,
DNA laddering) were observed only in highly puri¢ed nucleus
preparations from radio-sensitive, but not in radio-resistant,
myeloid leukemic cells [11]. These observations suggest that
nuclear sphingomyelinase and ceramide formation may con-
tribute to ionizing radiation-triggered apoptosis [11]. Intrigu-
ingly, sphingomyelinase activity present in the chromatin frac-
tion increases during liver regeneration after partial
hepatectomy as cells progress through the S-phase of the
cell cycle [12], further supporting the notion that there is an
intranuclear sphingomyelin cycle and that nuclear sphingoli-
pid metabolites may play a regulatory role in mediating cell
growth.
Of interest, sphingosine kinase (SPHK), the enzyme that
catalyzes the phosphorylation of sphingosine, is activated by
growth and survival factors, including platelet-derived growth
factor (PDGF), serum [13], nerve growth factor [14], and vi-
tamin D3 [15], as well as activation of protein kinase C [16],
resulting in increased intracellular levels of SPP. Abundant
evidence indicates that SPP promotes cell growth, prolifera-
tion, and resistance to apoptosis [17,18]. Moreover, it has
been suggested that balance between the sphingolipid metab-
olites ceramide/sphingosine and SPP may in£uence cell death
and survival [16,19].
Recently, two isoforms of mammalian sphingosine kinase
(SPHK1 and SPHK2) have been cloned and characterized
[20,21]. Overexpression of SPHK1 induces cell proliferation
by promoting the G1 to S-phase transition of the cell cycle,
as well as inhibiting the apoptotic response to serum depriva-
tion of ceramide [22]. Moreover, cells overexpressing SPHK1
acquire a transformed phenotype, as determined by focus for-
mation, colony growth in soft agar and the ability to form
tumors in NOD/SCID mice [23]. It is of interest that another
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lipid kinase, diacylglycerol kinase h, localizes to the nucleus
and plays a role in signal transduction [24,25]. Thus, we ex-
amined the possibility that SPHK, acting similarly to diacyl-
glycerol kinase, may be part of a lipid-signalling system in the
nucleus. Here we report that a signi¢cant fraction of total
cellular SPHK activity resides in the nuclei of Swiss 3T3 cells.
Moreover, the rapid increase in SPHK activity following stim-
ulation of PDGF that occurs after 5^10 min is followed by a
large increase in nuclear SPHK activity at much later times,
which correlates with progression of cells to the S-phase of the
cell cycle.
2. Materials and methods
2.1. Materials
Human PDGF-BB was purchased from Calbiochem (San Diego,
CA, USA), SPP and sphingosine were from Biomol Research Labo-
ratory Inc. (Plymouth Meeting, PA, USA). [Q-32P]ATP (3000 Ci/
mmol) was from Amersham (Arlington Heights, IL, USA). Serum
and medium were obtained from Bio£uids, Inc. (Rockville, MD,
USA). Insulin and transferrin were from Collaborative Research (Lex-
ington, MA, USA) and silica gel 60 G plates from EM Sciences
(Cherry Hill, NJ, USA). Bovine serum albumin (BSA) and reagents
for lactate dehydrogenase and K-glucosidase II assays were from Sig-
ma (St. Louis, MO, USA).
2.2. Cell culture
Swiss 3T3 and NIH 3T3 ¢broblasts were obtained from American
Type Culture Collection (Rockville, MD, USA) and cultured as pre-
viously described [26]. Swiss 3T3 ¢broblasts were seeded at a density
of 1.5U104 cells/cm2 in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 2 mM glutamine, penicillin (100
U/ml), streptomycin (100 Wg/ml), and 10% calf serum, refed after
2 days, and were used 5 days later when con£uent and quiescent.
For stimulation with PDGF, cells were washed twice with phos-
phate-bu¡ered saline (PBS) and cultured in serum-free medium con-
taining insulin (2 Wg/ml), transferrin (4 Wg/ml), and BSA (20 Wg/ml).
Cells were then stimulated with PDGF (10 ng/ml) or vehicle for the
indicated times.
2.3. Isolation of nuclei
Two methods were employed to purify intact nuclei from cells. In
each method, light microscopy was used to con¢rm that e⁄cient cell
lysis had occurred (greater than 90% in all cases).
2.3.1. Method I. This method for separating nuclei from cells was
carried out essentially as described [27], with the exception that
Tween-40 was omitted from the extraction bu¡er. Brie£y, cells were
washed with PBS, scraped in PBS, and then pelleted at 5000Ug for
5 min. Cells were resuspended in 400 Wl bu¡er A (10 mM HEPES, pH
7.5, 5 mM MgCl2, 15 mM KCl, 1 mM phenylmethylsulfonyl £uoride
(PMSF)) at 5U106 cells/ml, frozen in liquid nitrogen, thawed rapidly
at 37‡C, and then passed through a 25-gauge needle 15 times. The
resulting homogenate was layered on top of 200 Wl of a sucrose cush-
ion (50% sucrose in bu¡er A) and centrifuged at 15 000Ug for 3 min.
Nuclei-free cytoplasm was removed from above the sucrose layer.
Only intact nuclei pelleted through the cushion, as con¢rmed by light
microscopy.
2.3.2. Method II. Nuclei were also isolated by minor modi¢ca-
tions of a method described by Dignam et al. [28]. Cells were sus-
pended in 5 volumes bu¡er B (10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM PMSF, 0.5 mM dithiothreitol). After
15 min on ice, cells were lysed by passing ¢ve times through a
25-gauge needle. Nuclei were collected by centrifugation at 800Ug
for 5 min. The supernatant was then centrifuged at 16 000Ug for
10 min, and the resulting supernatant designated as the nuclei-free
cytoplasm.
2.4. Fractionation of nuclei
The nuclei obtained from methods I and II were further fraction-
ated into membrane and soluble components. Intact nuclei were re-
suspended in 200 Wl bu¡er A and sonicated three times at 200 W for
20 s, and then centrifuged at 16 000Ug for 10 min to separate the
nucleoplasm (supernatant) from the nuclear envelope and matrix (pel-
let). The nucleoplasm was subjected to an additional centrifugation at
100 000Ug for 30 min, and the resulting supernatant was designated
as the S-100 fraction.
To determine the purity of subcellular fractions, the activities of
speci¢c marker enzymes for cytosol and endoplasmic reticulum
(ER), lactate dehydrogenase and K-glucosidase II, respectively, were
measured. Lactate dehydrogenase activity was measured according to
the supplier’s protocol (Sigma). K-Glucosidase II activity was deter-
mined as described [29], with minor modi¢cations. Brie£y, 4-methyl-
umbelliferyl-K-D-glucoside was used as substrate in 100 mM phos-
phate bu¡er, pH 7.0, containing 0.1% Triton X-100, and assays
were carried out for 15 min at 37‡C. Reactions were terminated by
addition of ice-cold 250 mM potassium glycine, pH 10.3, and the
release of 4-methylumbelliferone was measured with a spectro£uorim-
eter (365 nm excitation, 450 nm emission).
2.5. Measurement of SPHK activity
SPHK activity in cytosolic or nuclear fractions was determined with
50 WM sphingosine, added as a complex with BSA (4 mg/ml),
[Q-32P]ATP (10 WCi, 1 mM) containing MgCl2 (10 mM), as previously
Fig. 1. E¡ect of PDGF on SPHK and DNA synthesis. Con£uent and quiescent cultures of Swiss 3T3 cells were washed in DMEM and incu-
bated in DMEM supplemented with BSA (20 Wg/ml), transferrin (5 Wg/ml), and insulin (4 Wg/ml) in the absence or the presence 10 ng/ml
PDGF. SPHK activity in cell lysates was measured after short- and long-term treatments with PDGF (open squares). Data are the mean þ S.D.
of triplicate determinations and are expressed as fold stimulation relative to untreated controls. In duplicate cultures, PDGF-treated cultures
were pulsed with [3H]thymidine 2 h prior to the indicated times, and incorporation into DNA was measured (¢lled circles). Data are expressed
as cpm incorporated per Wg protein. It should be noted that treatment of cells with insulin and transferrin had no e¡ect on SPHK activity or
on DNA synthesis.
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described [20]. Speci¢c activity is expressed as pmol SPP formed per
min per mg protein.
2.6. Measurement of DNA synthesis
Cells were pulsed for 2 h with 1 WCi of [3H]thymidine and incor-
poration of radioactivity into trichloroacetic acid-insoluble material
was measured as described [30]. Standard deviations were routinely
less then 10% of the mean.
2.7. Visualization of SPHK^green £uorescent protein (GFP)
NIH 3T3 ¢broblasts were plated on glass coverslips that had been
coated with 50 Wg/ml collagen and then transfected with 1 Wg of GFP^
SPHK1 fusion plasmid as described [22]. Cells were washed twice with
serum-free medium and starved for 3 h in serum-free medium con-
taining insulin (2 Wg/ml), transferrin (4 Wg/ml), and BSA (20 Wg/ml).
Cells were then treated with vehicle or 10 ng/ml PDGF at 37‡C for
24 h and ¢xed with 3.7% formaldehyde in PBS for 20 min. Confocal
£uorescent and Nomarski images were collected using an Olympus
microscope.
3. Results and discussion
3.1. Biphasic e¡ects of PDGF on SPHK activity
Previously, we found that PDGF rapidly stimulates SPHK
activity in Swiss 3T3 cells with subsequent increases in cellular
SPP levels [31]. Moreover, inhibition of SPHK by a compet-
itive inhibitor blocked PDGF-induced DNA synthesis, sug-
gesting that SPHK activation is important for the mitogenic
Fig. 2. Nuclear SPHK. Nuclei were puri¢ed from con£uent and quiescent 3T3 ¢broblasts by methods I (A) or II (B) as described in Section 2,
and SPHK, lactate dehydrogenase and K-glucosidase II activities were measured in the nuclei-free cytoplasm (open bars) and puri¢ed nuclei
(¢lled bars). Nuclei obtained from method I (C) or II (D) were further fractionated into nuclear envelope (open bars) and nucleoplasm
(hatched bars) and S-100 (¢lled bars) fractions, and SPHK, lactate dehydrogenase and K-glucosidase II activities measured. Data are expressed
as percent of total activity and are the mean þ S.D. of triplicate determinations. K-Glucosidase II activity was below detection limits in the
S-100 fraction. Similar results were obtained in three independent experiments.
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activity of PDGF [31]. The increase in SPHK activity ob-
served was transient, with activity returning to basal levels
within 1 h. We have now examined the e¡ects of PDGF on
SPHK activity over a much longer period. Interestingly,
PDGF induced a biphasic activation of SPHK. In agreement
with earlier studies [31], we observed a rapid and transient 1.7-
fold increase in SPHK activity, peaking at 5^10 min and de-
clining to control levels within 30 min (Fig. 1A). PDGF also
induced a second, two-fold increase of SPHK activity, peak-
ing at about 12^24 h after stimulation, which was more sus-
tained and only returned to basal levels after 36 h (Fig. 1B).
We also examined the time course of the increase in DNA
synthesis. PDGF signi¢cantly increased DNA synthesis in
quiescent cultures of Swiss 3T3 cells after 18 h of exposure,
reached a maximum after 24 h, and declined thereafter (Fig.
1B). This is consistent with numerous studies demonstrating
that there is a lag period of around 15 h preceding the entry
into the S-phase of the cell cycle in response to growth factors
(reviewed in [32]).
3.2. Nuclear SPHK activity
Recently, activation of nuclear sphingomyelinase, which hy-
drolyzes sphingomyelin to ceramide, has been implicated in
ionizing radiation-induced cell death in certain myelocytic cell
lines [11]. Because ceramide can be further metabolized to
sphingosine, the substrate for SPHK, it was important to
determine whether there might also be nuclear-associated
SPHK activity. To examine this possibility, intact nuclei
were isolated from cells by two di¡erent, non-detergent-based
methods. To rigorously con¢rm the purity of the nuclei, as-
says of marker enzymes speci¢cally localized in the cytosol
(lactate dehydrogenase) or in the ER (K-glucosidase II) were
performed. Both nuclear preparation methods e¡ectively re-
moved cytosolic contamination, with less then 6% of lactate
dehydrogenase activity found in the puri¢ed nuclei. However,
method I was more e¡ective at removing endoplasmic retic-
ulum contamination, as measured by K-glucosidase II activity,
with 9% contamination by this method versus 18% contami-
nation for method II (Fig. 2B). Therefore, method I was used
in subsequent experiments, though method II gave substan-
tially the same results for SPHK activity in nuclear fractions.
Interestingly, when SPHK activity in the subcellular fractions
was measured, approximately 30% of the total cellular SPHK
activity was found to be associated with the nucleus. This is
unlikely to be due to cytosolic contamination as shown by the
lactate dehydrogenase assays (Fig. 2A,B). Although it is di⁄-
cult to absolutely exclude the presence of contaminating mem-
branes in nuclei preparations, especially considering the con-
tinuous nature of the nuclear envelope with the ER, the
absence of ER-speci¢c K-glucosidase II activity revealed that
the presence of SPHK in the nucleus cannot be explained by
contamination with endoplasmic membrane.
As this is the ¢rst demonstration of the occurrence of
SPHK activity in the nucleus, it was important to determine
whether the SPHK activity was associated with the nuclear
envelope or in the nucleoplasm. To this end, puri¢ed nuclei
were further fractionated. Most of the nuclear SPHK activity
(s 75%) was found in the nucleoplasm. One-quarter of the
SPHK activity was found in the insoluble nuclear fraction,
suggesting that some SPHK is either tightly bound to mem-
branes or the nuclear matrix (Fig. 2C,D). To rule out the
possibility that the soluble nuclear fraction was contaminated
with a specialized subcompartment of the ER, the soluble
nuclear fraction was further centrifuged at 100 000Ug to pel-
let all membranes. All of the SPHK activity remained soluble,
while all of the ER marker, K-glucosidase II, was pelleted
(Fig. 2C,D). These results suggest that SPHK is not associated
with ER membranes, but rather is localized to the nucleo-
plasm.
3.3. Di¡erential e¡ects of PDGF on nuclear SPHK activity
The ¢nding that nuclei contain a relatively high basal
Fig. 3. E¡ects of PDGF on nuclear SPHK activity. Con£uent and quiescent 3T3 ¢broblasts were treated without (open bars) or with 10 ng/ml
PDGF (¢lled bars) for either 10 min (A) or 24 h (B). The cells were then harvested and nuclei prepared by method I. SPHK activity was mea-
sured in nuclei-free cytosol, nuclear envelope, and nucleoplasmic fractions. Data are the mean þ S.D. of triplicate assays and are expressed as
percent of total activity. Similar results were obtained in three independent experiments.
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SPHK activity, raised the possibility that nuclear SPHK ac-
tivity might also be regulated by PDGF. Thus, cells were
stimulated with PDGF for 10 min or 24 h and SPHK activity
determined in puri¢ed nuclei. As expected, treatment with
PDGF for 10 min stimulated SPHK activity in the nuclei-
free cytoplasm by 1.6-fold (Fig. 3A). However, no detectable
changes in either nuclear envelope or nucleoplasmic SPHK
activity were detected at this short time period. In contrast,
after 24 h of treatment, at a time during the second peak of
SPHK activity, there was a signi¢cant increase in SPHK ac-
tivity in both nuclei-free cytoplasm and nucleoplasm. These
data suggest that during progression of cells through the
S-phase of the cell cycle, stimulation of SPHK or transloca-
tion to the nucleus might play an important role.
3.4. Translocation of SPHK1 to the nucleus
We previously found that when cells were transfected with
SPKH1, the recombinant enzyme was stimulated to the same
extent by brief treatment with PDGF as endogenous SPHK
[22]. However, the e¡ects of PDGF stimulation on SPHK
activity at the longer time points corresponding to the second
peak of activity were not previously examined. We have now
used a SPHK1^GFP fusion protein to determine whether
SPHK1 is translocated to the nucleus after stimulation with
PDGF. In agreement with our previous study with c-myc-
tagged SPHK1 [22], SPHK1^GFP was di¡usely distributed
in the cytosol of 3T3 cells, with somewhat denser expression
in perinuclear sites. After 24 h treatment with PDGF, there
was a noticeable translocation of the SPHK1^GFP fusion
protein to the nuclear envelope (Fig. 4), as well as changes
in the ¢ne-granular distribution in the cytosol. SPHK1 has no
signal sequence or transmembrane domains, and can only
peripherally associate with the nuclear envelope. It should
be noted that disruption or puri¢ed nuclei released more
than 75% of the nuclear SPHK activity to the supernatant,
suggesting that SPHK1 is peripherally associated with the
inner nuclear membrane and that this interaction is disrupted
during fractionation of the nuclei into nucleoplasm, nuclear
envelope and matrix.
In conclusion, we present evidence here for the existence of
a signi¢cant pool of nuclear SPHK that increases upon stim-
ulation with the potent mitogen, PDGF. These observations
suggest a potential role for SPHK-dependent SPP synthesis in
nuclear-signalling pathways. This is a provocative suggestion,
as it is now well accepted that the main cellular targets of SPP
are receptors that reside in the plasma membrane. Abundant
evidence indicates that SPP is the ligand for G-protein-
coupled receptors, known as the EDG-1 family. To date,
¢ve di¡erent members have been identi¢ed, EDG-1, -3, -5,
-6, and -8 [17,33,34]. These receptors are developmentally
regulated, highly expressed in the cardiovascular and nervous
systems, and are coupled to a variety of G-proteins, and thus
Fig. 4. Cellular localization of SPHK1^GFP fusion protein. NIH 3T3 ¢broblasts were transiently transfected with SPHK1^GFP and after 24 h,
stimulated without or with 10 ng/ml PDGF for 24 h. Cells were examined by Nomarski to visualize the nucleus and by £uorescence microscopy
to localize the SPHK1^GFP fusion protein. GFP^SPHK1 was found to have identical enzymatic properties as the native enzyme.
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regulate diverse biological processes [17,18,33,34]. The exis-
tence of sphingomyelin metabolites [7,8,11] and SPHK in
the nucleus suggests independent functions of SPP in the nu-
cleus. The physiological signi¢cance of nuclear SPHK and its
product SPP, as well as the potential targets of SPP in the
nucleus is an important area for future investigation.
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